Boya Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Boya Lin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Eun Ha Choi
Plasma Bioscience Research Center/Department of Electrical and Biological Physics, Kwangwoon University, Seoul, 01897, South Korea
1 shared publication - Junjie Wang
Department of Radiation Oncology, Peking University Third Hospital, China
1 shared publication - Mengqing Li
Department Of Pathology, Peking University Shenzhen Hospital, Shenzhen, China
1 shared publication - Shubin Wang
Cancer Institute, Shenzhen Peking University-the Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Department of Oncology, Peking University Shenzhen Hospital; Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, Guangdong 518000, China
1 shared publication - Xiaodong Yang
Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Peking University Shenzhen Hospital, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen 518036, China
1 shared publication - Ya Jie Liu
Department of Radiation Oncology, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen Peking University-Hong Kong University of Science & Technology Medical Center, Shenzhen 518036, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 9014501
Low‐Temperature Plasma‐Activated Medium Inhibited Proliferation and Progression of Lung Cancer by Targeting the PI3K/Akt and MAPK Pathways
Low‐temperature plasma, an engineered technology to generate various reactive species, is actively studied in cancer treatment in recent years, yet mainly by using a traditional 2D cell culture system. In this study, we explored the effect of the plasma‐activated medium (PAM) on lung cancer cells in vitro and in vivo by using a 3D cell culture model. The results showed that PAM markedly inhibited 3D spheroid formation and downregulated stemness‐related gene expression. We found that reactive oxygen species (ROS) penetrated throughout the whole spheroids and induced cell death surrounding and in the core of the tumor spheroid. Besides, PAM treatment suppressed migration and invasion of lung cancer cells and downregulated epithelial‐mesenchymal transition‐ (EMT‐) related gene expression. In the mouse xenograft model, the tumor volume was significantly smaller in the PAM‐treated group compared with the control group. By using transcriptome sequencing, we found that PI3K/Akt and MAPK pathways were involved in the inhibition effects of PAM on lung cancer cells. Therefore, our results indicated that PAM exhibits potential anticancer effects on lung cancer and provides insight into further exploration of PAM‐induced cell death and translational preclinical use.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 9014501
Open AccessLow‐Temperature Plasma‐Activated Medium Inhibited Proliferation and Progression of Lung Cancer by Targeting the PI3K/Akt and MAPK Pathways
Low‐temperature plasma, an engineered technology to generate various reactive species, is actively studied in cancer treatment in recent years, yet mainly by using a traditional 2D cell culture system. In this study, we explored the effect of the plasma‐activated medium (PAM) on lung cancer cells in vitro and in vivo by using a 3D cell culture model. The results showed that PAM markedly inhibited 3D spheroid formation and downregulated stemness‐related gene expression. We found that reactive oxygen species (ROS) penetrated throughout the whole spheroids and induced cell death surrounding and in the core of the tumor spheroid. Besides, PAM treatment suppressed migration and invasion of lung cancer cells and downregulated epithelial‐mesenchymal transition‐ (EMT‐) related gene expression. In the mouse xenograft model, the tumor volume was significantly smaller in the PAM‐treated group compared with the control group. By using transcriptome sequencing, we found that PI3K/Akt and MAPK pathways were involved in the inhibition effects of PAM on lung cancer cells. Therefore, our results indicated that PAM exhibits potential anticancer effects on lung cancer and provides insight into further exploration of PAM‐induced cell death and translational preclinical use.